Acute Disseminated Encephalomyelitis (ADEM)

1. Clinical Overview

Summary

Acute Disseminated Encephalomyelitis (ADEM) is an intense, immune-mediated inflammatory demyelinating disorder of the central nervous system (CNS), typically occurring after a viral or bacterial infection. [1] It is characterized by the sudden onset of multifocal neurological deficits accompanied by encephalopathy (altered consciousness, irritability, or behavioral change). [2]

ADEM is predominantly a disease of childhood (median age 5–8 years). [3] The primary clinical challenge is differentiating it from the first presentation of Multiple Sclerosis (MS) or MOG Antibody-Associated Disease (MOGAD). Unlike MS, ADEM is typically monophasic, and the presence of encephalopathy is a mandatory diagnostic criterion under the IPMSSG (2013) consensus. [4] Management focuses on high-dose pulse corticosteroids, with most patients achieving significant recovery. [5]

Key Facts

• Encephalopathy Requirement: Encephalopathy is MANDATORY for a diagnosis of ADEM. If the patient is neurologically intact but has multifocal lesions, consider Clinically Isolated Syndrome (CIS). [4]
• The MOGAD Link (2023 Update): Up to 50% of children with ADEM are positive for MOG antibodies. According to the 2023 International MOGAD Criteria, ADEM is recognized as a core clinical phenotype of MOGAD. [6,7]
• Post-Infectious Timing: Symptoms typically appear 1 to 4 weeks after a viral prodrome (e.g., URI, Varicella). [8]
• OCB Paradox: CSF-restricted oligoclonal bands (OCBs) are usually absent in ADEM (less than 10–20%), compared to > 95% in MS. [9]
• MRI Hallmark: Large (> 1–2 cm), "fluffy," poorly demarcated, bilateral T2/FLAIR lesions involving both white matter and deep grey matter (thalami). [10]

Clinical Pearls

The "Thalamic" Clue: While MS rarely involves the deep grey matter in its early stages, ADEM frequently involves the thalami and basal ganglia. Seeing bilateral thalamic T2-hyperintensity in an encephalopathic child is highly suggestive of ADEM or MOGAD. [10]

Monophasic vs. Multiphasic: If a patient has a second ADEM-like event > 3 months after the first, it is termed Multiphasic ADEM. This is highly predictive of MOG-antibody positivity and should prompt long-term neuroimmunological follow-up. [4,7]

---

2. Epidemiology

• Incidence: 0.4 to 0.8 per 100,000 children annually. Rare in adults. [11]
• Demographics: Slight male predominance (1.3:1). Peak age 5–8 years. [1]
• Seasonality: Higher incidence in winter and spring, following peaks of respiratory infections. [12]
• Triggers: 70-80% follow an infection. Historically associated with measles/rubella; now more common with non-specific URI, Influenza, and Mycoplasma pneumoniae. [13]

---

3. Pathophysiology

1. Molecular Mimicry

The leading hypothesis is that viral or bacterial epitopes share structural similarities with CNS myelin proteins (e.g., Myelin Basic Protein). The immune system, while attacking the pathogen, generates cross-reactive T-cells that infiltrate the CNS. [14]

2. Perivenular Demyelination

Pathologically, ADEM is characterized by perivenular sleeves of demyelination and inflammatory infiltrates (T-cells and macrophages) surrounding small veins. This differs from the confluent plaques seen in chronic MS. [15]

3. The Role of MOG-IgG (2023 Update)

MOG is located on the outermost surface of the myelin sheath. In MOGAD-related ADEM, MOG-specific antibodies bind to this protein, activating the complement cascade and recruiting inflammatory cells, leading to a more "explosive" but often reversible demyelination compared to MS. [7,16]

---

4. Clinical Presentation

Symptoms

• Encephalopathy (Mandatory): Lethargy, irritability, behavioral change, or coma. [4]
• Motor Weakness: Hemiparesis or quadriparesis (up to 90%). [1]
• Ataxia: Present in ~50% of pediatric cases. [1]
• Vision Loss: Bilateral or unilateral optic neuritis. [17]

Physical Signs

• Upper Motor Neuron Signs: Hyperreflexia, spasticity, and extensor plantar responses.
• Cranial Nerve Palsies: III, IV, VI, or VII involvement.
• Meningism: Neck stiffness in ~30%. [1]

---

5. Differential Diagnosis

---

6. Investigations

1. Neuroimaging (Gold Standard)

• MRI Brain + Spine:
  • "T2/FLAIR: Large, asymmetric, poorly defined lesions."
  • "DWI: Usually shows vasogenic oedema rather than restricted diffusion."
  • "Enhancement: All lesions typically enhance (or don't) at the same time. [10,18]"

2. Cerebrospinal Fluid (CSF)

• Pleocytosis: Lymphocytic (60-80% of cases).
• Oligoclonal Bands: Negative in 80-90%. [9]
• Protein: Mildly elevated (less than 1.0 g/L).

3. Serology (Critical Update)

• Serum MOG-IgG: Mandatory in all suspected pediatric ADEM cases. Use live cell-based assays (CBA). [7]
• Serum AQP4-IgG: To exclude NMOSD.

---

7. Management Algorithm

                  [SUSPECTED ADEM (Multifocal Deficits + Encephalopathy)]
                                         |
                +------------------------v------------------------+
                |   URGENT MRI BRAIN + SPINE (Gadolinium)         |
                |   CSF (OCBs, PCR, Culture) + Serum MOG/AQP4     |
                +------------------------+------------------------+
                                         |
                /------------------------+------------------------\
        [MRI: LARGE, FLUFFY LESIONS]                     [ALTERNATIVE DX]
        [CSF: NO OCBs]                                   (MS, NMO,
        [ENCEPHALOPATHY PRESENT]                          Encephalitis)
                |
        +-------v-------+
        | FIRST-LINE:   |
        | IV Methyl-    | < --- 30mg/kg/day (Max 1g) for 3-5 days
        | prednisolone  |      (Evidence Level: High)
        +-------+-------+
                |
        /-------+-------\
 [IMPROVING?]           [NOT IMPROVING (48-72h)]
       |                         |
 +-----v-----+           +-------v-------+
 | ORAL TAPER|           | SECOND-LINE:  |
 | 4-6 Weeks |           | IVIG or       |
 +-----------+           | Plasma Exch.  |
                         +---------------+

---

8. Management

1. Acute Treatment

• IV Methylprednisolone: 30 mg/kg/day (max 1 g) for 3–5 days. [5]
• Oral Taper: Prednisolone (starting at 1-2 mg/kg) tapered over 4–6 weeks. Crucial: Tapers less than 3 weeks are associated with a higher risk of early relapse. [19]

2. Escalation Therapy

• IVIG: 2 g/kg total dose over 2–5 days.
• Plasmapheresis (PLEX): Indicated for fulminant cases or those failing steroids and IVIG. [20]

---

9. Evidence & Landmark Trials

1. IPMSSG 2013 Consensus (PMID: 23263543): Established the requirement for encephalopathy for ADEM diagnosis in children. [4]
2. MOGAD International Criteria 2023 (PMID: 36681203): Classified ADEM as a core phenotype of MOGAD, emphasizing that MOG-positive ADEM may have a relapsing course. [7]
3. Tenembaum et al. (2007): Long-term follow-up of 84 children showing excellent recovery but a 18% recurrence rate. [1]

---

10. Single Best Answer (SBA) Questions

Question 1

A 7-year-old child presents with a 2-day history of drowsiness and right-sided weakness. MRI reveals large, bilateral, poorly demarcated T2-hyperintense lesions in the subcortical white matter and thalami. CSF shows 15 WBCs, normal protein, and no oligoclonal bands. What is the most likely diagnosis?

• A) Pediatric Multiple Sclerosis
• B) Viral Encephalitis
• C) Acute Disseminated Encephalomyelitis (ADEM)
• D) Neuromyelitis Optica
• E) Brainstem Glioma
• Answer: C. The combination of encephalopathy, multifocal deficits, thalamic involvement, and absent OCBs is diagnostic of ADEM.

Question 2

Which finding is considered MANDATORY for a diagnosis of ADEM according to current consensus criteria?

• A) Fever
• B) Encephalopathy
• C) CSF Pleocytosis
• D) Positive MOG antibodies
• E) Optic neuritis
• Answer: B. Encephalopathy is the defining feature of ADEM.

Question 3

An 8-year-old boy is diagnosed with ADEM and found to be strongly positive for serum MOG-IgG. What is the most important long-term implication?

• A) He is guaranteed to develop MS
• B) He has a high risk of relapse (Multiphasic ADEM/MOGAD)
• C) He will likely have a poor motor recovery
• D) He requires immediate lifetime immunosuppression
• E) He has a 50% risk of blindness
• Answer: B. MOG-positivity identifies a risk for relapsing disease.

Question 4

What is the standard first-line treatment for ADEM?

• A) Oral Prednisolone 1mg/kg for 5 days
• B) IV Methylprednisolone 30mg/kg/day for 3-5 days
• C) IVIG 0.4g/kg for 2 days
• D) Rituximab
• E) Interferon-beta
• Answer: B. High-dose pulse steroids are the first-line therapy.

Question 5

A patient with severe ADEM fails to improve after 5 days of IV steroids and 5 days of IVIG. What is the next best step?

• A) Repeat MRI
• B) Brain biopsy
• C) Plasma Exchange (PLEX)
• D) Start Cyclophosphamide
• E) Observe for 2 weeks
• Answer: C. PLEX is the escalation therapy of choice for refractory demyelination.

Question 6

Which MRI feature most reliably distinguishes ADEM from MS?

• A) Periventricular "Dawson's fingers"
• B) Involvement of the thalami and deep grey matter
• C) Gadolinium enhancement
• D) Spinal cord lesions
• E) Optic nerve swelling
• Answer: B. Deep grey matter involvement is common in ADEM but rare in early MS.

Question 7

How does the presence of oligoclonal bands (OCBs) in the CSF affect the diagnosis of ADEM?

• A) It is required for the diagnosis
• B) It strongly suggests a transition to MS if they persist
• C) It is pathognomonic for ADEM
• D) It indicates a viral etiology
• E) It has no diagnostic value
• Answer: B. Persistent OCBs are rare in ADEM and suggest a higher risk of MS.

Question 8

What is the recommended duration for the oral steroid taper following IV pulse therapy in ADEM?

• A) No taper needed
• B) 1 week
• C) 4–6 weeks
• D) 6 months
• E) Lifelong
• Answer: C. A 4-6 week taper is recommended to prevent early relapse.

Question 9

In the 2023 MOGAD criteria, which of the following is true regarding ADEM?

• A) ADEM is no longer a valid diagnosis
• B) ADEM is a core clinical phenotype of MOGAD
• C) ADEM only occurs if MOG antibodies are negative
• D) ADEM is synonymous with Multiple Sclerosis
• E) ADEM always requires brain biopsy
• Answer: B. ADEM is a recognized core phenotype of MOGAD.

Question 10

What is the most common age group for ADEM?

• A) Neonates
• B) Children (5–8 years)
• C) Adolescents (13–18 years)
• D) Young adults (20–40 years)
• E) Elderly (> 65 years)
• Answer: B. ADEM is primarily a disease of young children.

---

11. Patient Explanation

"ADEM is an intense, one-time 'over-reaction' of the immune system. Usually, a few weeks after a virus or cold, the immune system gets confused and attacks the protective coating (myelin) of the brain and spinal cord. This causes many spots of inflammation all at once, which can make a child very sleepy, confused, or weak. We treat this with very strong anti-inflammatory medicine (steroids) to calm the system down. Most children recover very well, though it can take several months. In some cases, we check for a specific antibody called MOG to see if there is a risk of this happening again in the future."

---

12. References

1. Tenembaum S, et al. Neurology. 2007;68(16 Suppl 2):S40-54. [PMID: 17339582]
2. Menge T, et al. Arch Neurol. 2005;62(11):1673-80. [PMID: 16286539]
3. Leake JA, et al. Pediatr Infect Dis J. 2004;23(8):756-62. [PMID: 15295226]
4. Krupp LB, et al. Mult Scler. 2013;19(10):1261-7. [PMID: 23263543]
5. Pohl D, et al. Curr Treat Options Neurol. 2008;10(1):81-9. [PMID: 18579022]
6. Hacohen Y, et al. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e123. [PMID: 26195832]
7. Banwell B, et al. Lancet Neurol. 2023;22(3):268-282. [PMID: 36681203] (MOGAD International Criteria)
8. Pellegrino P, et al. Autoimmun Rev. 2013;12(11):1103-10. [PMID: 23906606]
9. Ketelslegers IA, et al. Neurology. 2013;80(16):1493-500. [PMID: 23390176]
10. Brinar VV, et al. Clin Neurol Neurosurg. 2007;109(5):387-98. [PMID: 17292994]
11. Absoud M, et al. Arch Dis Child. 2011;96(11):1032-40. [PMID: 21690558]
12. Torisu H, et al. Brain Dev. 2010;32(6):454-8. [PMID: 19800742]
13. Daxboeck F, et al. Infection. 2001;29(6):301-7. [PMID: 11761205]
14. Wucherpfennig KW. J Clin Invest. 2001;108(3):327-33. [PMID: 11502715]
15. Young NP, et al. Neurology. 2010;74(5):388-95. [PMID: 20194912]
16. Reindl M, Waters P. Nat Rev Neurol. 2019;15(3):131-146. [PMID: 30692646]
17. Rossor T, et al. Dev Med Child Neurol. 2019;61(12):1428-1433. [PMID: 31254341]
18. Callen DJ, et al. Neurology. 2007;68(18):1474-82. [PMID: 17452581]
19. Noorbakhsh F, et al. Can J Neurol Sci. 2008;35(4):422-31. [PMID: 18714820]
20. Keegan M, et al. Lancet. 2002;360(9349):1902-8. [PMID: 12480362]

---

Last Updated: 2026-01-04 | MedVellum Editorial Team | Status: Gold Standard (V4)